- Home
- MITQ vs ACXP Comparison
MITQ vs ACXP Comparison
Compare MITQ & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITQ
- ACXP
- Stock Information
- Founded
- MITQ N/A
- ACXP 2017
- Country
- MITQ United States
- ACXP United States
- Employees
- MITQ N/A
- ACXP N/A
- Industry
- MITQ Telecommunications Equipment
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- MITQ Telecommunications
- ACXP Health Care
- Exchange
- MITQ Nasdaq
- ACXP Nasdaq
- Market Cap
- MITQ 7.3M
- ACXP 8.4M
- IPO Year
- MITQ 2021
- ACXP 2021
- Fundamental
- Price
- MITQ $0.57
- ACXP $0.40
- Analyst Decision
- MITQ
- ACXP Strong Buy
- Analyst Count
- MITQ 0
- ACXP 1
- Target Price
- MITQ N/A
- ACXP $12.00
- AVG Volume (30 Days)
- MITQ 343.7K
- ACXP 135.9K
- Earning Date
- MITQ 05-14-2025
- ACXP 05-13-2025
- Dividend Yield
- MITQ N/A
- ACXP N/A
- EPS Growth
- MITQ N/A
- ACXP N/A
- EPS
- MITQ N/A
- ACXP N/A
- Revenue
- MITQ $18,932,000.00
- ACXP N/A
- Revenue This Year
- MITQ N/A
- ACXP N/A
- Revenue Next Year
- MITQ N/A
- ACXP N/A
- P/E Ratio
- MITQ N/A
- ACXP N/A
- Revenue Growth
- MITQ N/A
- ACXP N/A
- 52 Week Low
- MITQ $0.42
- ACXP $0.30
- 52 Week High
- MITQ $1.55
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- MITQ 45.85
- ACXP 48.44
- Support Level
- MITQ $0.52
- ACXP $0.36
- Resistance Level
- MITQ $0.69
- ACXP $0.45
- Average True Range (ATR)
- MITQ 0.09
- ACXP 0.02
- MACD
- MITQ -0.01
- ACXP 0.02
- Stochastic Oscillator
- MITQ 16.38
- ACXP 97.32
About MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.